Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose of the trial is to determine the long-term safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.
Condition or disease
The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Previously participated in a trial of RPC1063 for UC and meet the criteria for participation in the open label extension as outlined in the prior trial
Female patients of childbearing potential:
Must agree to practice a highly effective method of contraception throughout the trial until completion of the safety follow-up visit. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly. Acceptable methods of birth control in the trial are the following:
combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal
progestogen-only hormonal contraception associated with inhibition of ovula-tion, which may be oral, injectable, or implantable
placement of an intrauterine device (IUD)
placement of an intrauterine hormone-releasing system (IUS)
bilateral tubal occlusion
Must agree to use a latex condom during sexual contact with women of childbearing po-tential while participating in the trial until completion of the safety follow-up visit.
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not ac-ceptable methods of contraception. Female condom and male condom should not be used together.
Must provide written informed consent and have the ability to be compliant with the schedule of protocol assessments, which must be obtained prior to any trial-related procedures.
Have received any of the following therapies since the first dose of investigational drug in the prior RPC1063 trial:
Treatment with a biologic agent
Treatment with an investigational agent other than RPC1063
Treatment with D-penicillamine, leflunomide, thalidomide, natalizumab or fingolimod
Treatment with lymphocyte-depleting therapies (e.g., Campath, anti-CD4, cladribine, rituximab, ocrelizumab, cyclophosphamide, mitoxantrone, total body irradiation, bone marrow transplantation, alemtuzumab, daclizumab)
Treatment with a live vaccine within 4 weeks prior to Visit 1 of this trial
Are currently receiving or require initiation of any of the following therapies:
Treatment with corticosteroids at a dose that exceeds the prednisone equivalent of >40 mg
Treatment with immunosuppressive agents (eg, azathioprine, 6-MP, or methotrexate)
Chronic non-steroidal anti-inflammatory drug (NSAID) use (Note: occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, or menstru-al cramps] and aspirin up to 325 mg/day is permitted)
Treatment with Class Ia or Class III anti-arrhythmic drugs or treatment with two or more agents in combination known to prolong PR interval
Pregnancy, lactation, or a positive serum beta human chorionic gonadotropin (hCG)
Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric or other major systemic disease making implementation of the protocol or interpretation of the trial difficult or that would put the patient at risk by participating in the trial or that would have required a patient to discontinue treatment in previous RPC1063 trial
Clinically relevant cardiovascular conditions, including history or presence of recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, Class III/IV heart failure, sick sinus syndrome, or severe untreated sleep apnea
Liver function impairment or persisting elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN), or direct bilirubin > 3 times the ULN